Tirzepatide vs. Semaglutide: What the Trial Data Actually Shows (and What It Doesn’t) is best understood as a clinical decision topic, not a shortcut. The evidence, pharmacy source, dose plan, contraindications, and follow-up matter more than any single success story online.
A patient I’ll call David sat across from his endocrinologist in a suburban Dallas clinic last October, holding printouts from three different Reddit threads and a TikTok transcript. He’d been on semaglutide 1.7 mg for five months, lost 11% of his body weight, then stalled. His question was simple: “Should I switch to tirzepatide?” His endocrinologist’s answer took 25 minutes and covered pharmacology, insurance formularies, compounding regulations, and the specific quirks of his lipid panel. That conversation is the one a lot of people are trying to have right now, and the internet is doing a mediocre job of supplying it.
So Here is the practical read: followed by the longer one.
Tirzepatide produces greater mean weight loss than semaglutide in head-to-head trial data. SURMOUNT-1 (Jastreboff et al., NEJM 2022) reported up to 20.9% mean body weight reduction at the 15 mg dose over 72 weeks. STEP-1 (Wilding et al., NEJM 2021) reported 14.9% with semaglutide 2.4 mg over 68 weeks. SURMOUNT-5 compared them directly and confirmed the gap. But “greater mean weight loss” is a population statistic, and you are not a population. The real question is which molecule, at which dose, in which formulation, works for your body, your budget, and your risk profile.
One Receptor vs. Two: Why It Probably Matters
Semaglutide activates GLP-1 receptors. Tirzepatide activates both GLP-1 and GIP receptors.
Whether that second receptor is doing meaningful clinical work was genuinely debated until SURMOUNT-5 provided head-to-head numbers. At this point, the weight of evidence says yes, dual agonism contributes to the larger weight loss signal. The mechanism likely involves enhanced insulin sensitivity and possibly different effects on appetite-regulating pathways, though the GIP side of the story is still being worked out.
The catch is that most of the gastrointestinal side effects come from GLP-1 receptor activity, which both drugs share. So adding a receptor doesn’t necessarily add tolerability problems, but it doesn’t solve them either. Nausea, diarrhea, constipation, vomiting: these track similarly across both molecules in trial data. Some individual patients clearly do better on one than the other, but predicting who will tolerate which remains more art than science.
The Dosing Ladder (and Why Compounding Changes It)
Tirzepatide’s labeled titration schedule looks like this:
| Phase | Dose | Duration | What to Expect | |—|—|—|—| | Initiation | 2.5 mg weekly | Weeks 1-4 | GI acclimation. Minimal weight loss. Don’t panic. | | Step 1 | 5 mg weekly | Weeks 5-8 | First real appetite suppression for most patients | | Step 2 | 7.5 mg weekly | Weeks 9-12 | Some prescribers hold here if response is solid | | Step 3 | 10 mg weekly | Weeks 13-16 | Common long-term maintenance dose | | Step 4 | 12.5 mg weekly | Weeks 17-20 | For patients whose response is fading | | Step 5 | 15 mg weekly | Week 21+ | Maximum labeled dose. Not everyone needs it. |
The 2.5 mg starting dose is not a therapeutic dose. It exists to let your gut adjust. Patients who expect dramatic results during month one are almost always disappointed. That expectation mismatch is one of the most common reasons people abandon therapy prematurely.
Not every patient needs to reach 15 mg. Plenty stabilize at 5 or 10 mg once they hit goal weight, balancing ongoing benefit against side effects and cost.
Here’s where compounding enters the picture. Branded autoinjectors come in fixed doses. Compounded preparations from 503A or 503B pharmacies can be formulated at intermediate doses (6.25 mg, 8.75 mg) that don’t exist in the branded pen lineup. For patients who can tolerate 5 mg fine but get slammed by nausea at 7.5 mg, a 6.25 mg step can be the difference between staying on therapy and quitting. That flexibility is a genuine clinical advantage, not a marketing gimmick.
Branded vs. Compounded: The Boring Truth
The active molecule is the same. The differences are in manufacturing oversight, regulatory status, packaging, and price.
Branded Zepbound and Mounjaro are FDA-approved finished drugs made by Eli Lilly under cGMP standards with full post-marketing surveillance. Compounded versions are produced by state-licensed 503A pharmacies (patient-specific prescriptions) or 503B outsourcing facilities (which operate under cGMP inspection and can produce office stock).
Compounded preparations are not FDA-evaluated for safety, efficacy, or quality in the way branded products are. The regulatory framework depends on state pharmacy boards, federal 503A/503B requirements, and individual prescriber judgment.
If you’re considering a compounded option, the questions worth asking are specific: Is the pharmacy state-licensed? Does a real clinician (not a checkbox form) evaluate you before prescribing? Is pricing transparent, or buried behind a “consultation fee” that magically equals the drug cost? A more detailed treatment of these questions, along with dosing protocols and side effect management strategies, is available in the FormBlends comparison guide, which covers the regulatory framework more thoroughly than I can here.
Side Effects: What the Percentages Mean in Practice
GI symptoms dominate.
| Symptom | Frequency in Trials | Timing | What Helps | |—|—|—|—| | Nausea | 30-45% | Worst in first 4-8 weeks and after dose increases | Smaller meals, lower fat intake, water sipping, antiemetic if persistent | | Diarrhea | 15-23% | Variable | Hydration, electrolyte monitoring, bland diet temporarily | | Constipation | 10-17% | Often develops as GI motility slows | 25-35g fiber daily, hydration, magnesium if clinician approves | | Vomiting | 8-13% | Concentrated in early weeks and escalations | Hold dose, contact prescriber if it persists beyond 48 hours | | Reflux | 7-12% | Throughout therapy (underreported) | No eating within 3 hours of bed, raise head of bed | | Fatigue | Variable | Early weeks | Usually resolves; check ferritin, B12, thyroid if it lingers |
Those nausea numbers (30-45%) sound alarming, but severity matters more than incidence. Most patients describe it as manageable. The ones who end up miserable are often titrating too fast, eating large fatty meals, or both.
Serious labeled risks include pancreatitis, gallbladder disease, severe hypoglycemia (particularly when stacked with insulin or sulfonylureas), kidney injury from dehydration, and a boxed warning for medullary thyroid carcinoma based on rodent studies. Severe abdominal pain radiating to the back is a “call your doctor now” symptom, not a “wait and see” one.
Reasonable baseline labs before starting: comprehensive metabolic panel, HbA1c and fasting glucose, lipid panel, TSH, lipase (especially with any pancreatitis history), and CBC. Repeat at 12-16 weeks, then roughly every six months once stable.
Switching Between the Two
This comes up constantly. Three common scenarios:
Plateau on semaglutide, considering tirzepatide: Start tirzepatide at 2.5 mg the week after your last semaglutide dose. Do not try to dose-match. The molecules are different; the numbers don’t translate.
Switching to semaglutide for cost or insurance reasons: Begin at 0.25 mg weekly. Yes, even if you were on high-dose tirzepatide. Expect a re-acclimation period similar to starting fresh.
Switching because of side effects: This is where people get it wrong most often. If the side effect is driven by GLP-1 receptor activity (nausea, for instance), switching to the other GLP-1 agonist may not help. It’s like changing brands of hot sauce and hoping your stomach won’t notice the capsaicin. Address the side effect first: slow the titration, adjust diet, hold at a lower dose. Switching is sometimes the answer, but it shouldn’t be the first answer.
Switching is not a DIY project. It requires clinical supervision, dose pacing, monitoring, and managing the gap between drugs.
Do not switch during pregnancy planning. Do not switch if you have absolute contraindications to both molecules. These seem obvious, but I mention them because people ask.
When You Need a Clinician, Not a Blog Post
Before starting, talk to a clinician if you have: personal or family history of medullary thyroid carcinoma or MEN 2 syndrome, history of pancreatitis, severe gastroparesis, severe liver impairment, current pregnancy or active pregnancy planning, or current use of insulin or sulfonylureas without coordinated diabetes management.
During therapy, contact a clinician for: severe persistent abdominal pain (especially radiating to the back), dehydration signs from vomiting or diarrhea, vision changes (particularly in diabetic patients), severe persistent reflux, signs of allergic reaction, or anything that feels qualitatively different from normal titration side effects.
Routine check-ins every 12-16 weeks during active titration and every 6 months once stable is a reasonable cadence. This is not the kind of medication you should be managing on autopilot.
Frequently Asked Questions
Which produces more weight loss?
Tirzepatide, on average. SURMOUNT-5 showed greater mean weight loss vs. semaglutide over 72 weeks. SURMOUNT-1 reported up to 20.9% at 15 mg tirzepatide; STEP-1 reported 14.9% at semaglutide 2.4 mg. Individual results vary considerably within both groups.
Which is better tolerated?
GI side effect profiles overlap significantly. Neither molecule has a clear tolerability advantage at the population level, but individual patients sometimes do much better on one than the other.
What’s the dosing difference?
Tirzepatide: 2.5, 5, 7.5, 10, 12.5, 15 mg weekly. Semaglutide (Wegovy): 0.25, 0.5, 1.0, 1.7, 2.4 mg weekly. The dose numbers are not comparable across molecules.
Which is cheaper?
Branded list prices are in similar ranges. Compounded versions of either are typically less expensive. Manufacturer savings programs exist but vary. The actual out-of-pocket number depends on insurance, pharmacy, and formulation.
Can I take both simultaneously?
No. Combining GLP-1 agonists is not supported by trial data and is not standard clinical practice.
Which works faster?
Appetite suppression onset is similar, typically within 2-4 weeks. Meaningful weight loss accelerates as the dose climbs through the titration schedule.
Is one better for people with type 2 diabetes specifically?
Both have strong diabetes data (SURPASS trials for tirzepatide, SUSTAIN/STEP trials for semaglutide). Tirzepatide showed superior A1c reduction in head-to-head comparisons, but the choice also depends on insurance coverage, formulary access, and individual response.
Important regulatory note. Compounded tirzepatide is not FDA-approved. It is prepared by licensed 503A or 503B pharmacies for individual patients based on a prescriber’s clinical judgment. Compounded preparations are not evaluated by the FDA for safety, efficacy, or quality the way branded products are. Research suggests outcomes vary between patients, and any decision to begin, modify, or discontinue therapy should occur in coordination with a licensed clinician who can review your medical history, current medications, and laboratory values.
